Silvana Mouron - Publications

A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer.

Journal: Cancer research communications

Published: July 25, 2025

Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations.

Journal: NPJ precision oncology

Published: May 20, 2025

The automated computational workflow QUICHE reveals structural definitions of antitumor responses in triple-negative breast cancer.

Journal: Nature cancer

Published: April 02, 2025

High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 14, 2024

Osteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti-PD-L1 refractoriness in breast cancer models.

Journal: The Journal of clinical investigation

Published: February 01, 2024

Distribution of PD-L1, TROP2 and HER2- "lowness" in early triple-negative breast cancer: an opportunity for treatment de-escalation.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 21, 2023

Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement.

Journal: EClinicalMedicine

Published: February 27, 2023

p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor-positive breast cancer.

Journal: JNCI cancer spectrum

Published: December 30, 2022

Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: August 24, 2022

RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.

Journal: EMBO molecular medicine

Published: August 08, 2022

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A.

Journal: Nature communications

Published: January 11, 2022

A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.

Journal: EMBO molecular medicine

Published: May 14, 2021